ArticleThe Journal of pharmacology and experimental therapeutics2019
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Trypanosoma cruzi Exploits E- and P-Selectins To Migrate Across Endothelial Cells and Extracellular Matrix Proteins.Infection and immunity · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Tamar LedouxProgram in Pharmacology and Experimental Therapeutics (T.L., S.P., M.P.) and Program in Immunology (D.A., R.S., N.N., P.A.), Sackler School of Graduate Biomedical Sciences and Departments of Developmental, Molecular and Chemical Biology (T.L., D.A., R.S., S.P., M.P.) and Immunology (N.N., P.A.), Tufts University, Boston, Massachusetts; and Molecular Cardiology Research Institute and Division of Cardiology (R.B.), Tufts Medical Center, Boston, Massachusetts.
Daniel AridgidesProgram in Pharmacology and Experimental Therapeutics (T.L., S.P., M.P.) and Program in Immunology (D.A., R.S., N.N., P.A.), Sackler School of Graduate Biomedical Sciences and Departments of Developmental, Molecular and Chemical Biology (T.L., D.A., R.S., S.P., M.P.) and Immunology (N.N., P.A.), Tufts University, Boston, Massachusetts; and Molecular Cardiology Research Institute and Division of Cardiology (R.B.), Tufts Medical Center, Boston, Massachusetts.
Ryan SalvadorProgram in Pharmacology and Experimental Therapeutics (T.L., S.P., M.P.) and Program in Immunology (D.A., R.S., N.N., P.A.), Sackler School of Graduate Biomedical Sciences and Departments of Developmental, Molecular and Chemical Biology (T.L., D.A., R.S., S.P., M.P.) and Immunology (N.N., P.A.), Tufts University, Boston, Massachusetts; and Molecular Cardiology Research Institute and Division of Cardiology (R.B.), Tufts Medical Center, Boston, Massachusetts.
Njabulo NgwenyamaProgram in Pharmacology and Experimental Therapeutics (T.L., S.P., M.P.) and Program in Immunology (D.A., R.S., N.N., P.A.), Sackler School of Graduate Biomedical Sciences and Departments of Developmental, Molecular and Chemical Biology (T.L., D.A., R.S., S.P., M.P.) and Immunology (N.N., P.A.), Tufts University, Boston, Massachusetts; and Molecular Cardiology Research Institute and Division of Cardiology (R.B.), Tufts Medical Center, Boston, Massachusetts.
Smaro PanagiotidouProgram in Pharmacology and Experimental Therapeutics (T.L., S.P., M.P.) and Program in Immunology (D.A., R.S., N.N., P.A.), Sackler School of Graduate Biomedical Sciences and Departments of Developmental, Molecular and Chemical Biology (T.L., D.A., R.S., S.P., M.P.) and Immunology (N.N., P.A.), Tufts University, Boston, Massachusetts; and Molecular Cardiology Research Institute and Division of Cardiology (R.B.), Tufts Medical Center, Boston, Massachusetts.
Pilar AlcaideProgram in Pharmacology and Experimental Therapeutics (T.L., S.P., M.P.) and Program in Immunology (D.A., R.S., N.N., P.A.), Sackler School of Graduate Biomedical Sciences and Departments of Developmental, Molecular and Chemical Biology (T.L., D.A., R.S., S.P., M.P.) and Immunology (N.N., P.A.), Tufts University, Boston, Massachusetts; and Molecular Cardiology Research Institute and Division of Cardiology (R.B.), Tufts Medical Center, Boston, Massachusetts.
Robert M BlantonProgram in Pharmacology and Experimental Therapeutics (T.L., S.P., M.P.) and Program in Immunology (D.A., R.S., N.N., P.A.), Sackler School of Graduate Biomedical Sciences and Departments of Developmental, Molecular and Chemical Biology (T.L., D.A., R.S., S.P., M.P.) and Immunology (N.N., P.A.), Tufts University, Boston, Massachusetts; and Molecular Cardiology Research Institute and Division of Cardiology (R.B.), Tufts Medical Center, Boston, Massachusetts.
Mercio A PerrinProgram in Pharmacology and Experimental Therapeutics (T.L., S.P., M.P.) and Program in Immunology (D.A., R.S., N.N., P.A.), Sackler School of Graduate Biomedical Sciences and Departments of Developmental, Molecular and Chemical Biology (T.L., D.A., R.S., S.P., M.P.) and Immunology (N.N., P.A.), Tufts University, Boston, Massachusetts; and Molecular Cardiology Research Institute and Division of Cardiology (R.B.), Tufts Medical Center, Boston, Massachusetts Mercio.Perrin@tufts.edu.
Tufts Medical Center · USTufts University · US
Funding
Cardiac Cell Entry-Inhibition and Protection Therapy for Chronic Chagas DiseaseR01AI113075 · NIAID · TUFTS UNIVERSITY BOSTON · PI PERRIN, MERCIO A · 2014 to 2018
$2.2MT Cell Mediated Immune Responses as a Regulator of Heart FailureR01HL123658 · NHLBI · TUFTS UNIVERSITY BOSTON · PI ALCAIDE ALONSO, MARIA PILAR · 2014 to 2018
$2.2MNovel Protein Kinase GI Substrates in Cardiac Remodeling and Blood Pressure ControlR01HL131831 · NHLBI · TUFTS MEDICAL CENTER · PI BLANTON, ROBERT MORRIS · 2016 to 2020
$2.1MPharmacodynamic modeling of antibiotics on cystic fibrosis P. aeruginosa biofilmsR01AI097380 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YANG, KATHERINE Y. · 2012 to 2016
$1.9MDeciphering the mechanisms of CD4 T cell activation in nonischemic heart failureF31HL140883 · NHLBI · TUFTS UNIVERSITY BOSTON · PI NGWENYAMA, NJABULO · 2018 to 2019
$70kEXPANSION AND CHARACTERIZATION OF HIV SPECIFIC CD4 CELLSF32AI009738 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ROSENBERG, ERIC S · 1996 to 1997
–NHLBI NIH HHS F31 HL140883NHLBI NIH HHS R01 HL123658NHLBI NIH HHS R01 HL131831NIAID NIH HHS F32 AI009738NIAID NIH HHS R01 AI097380NIAID NIH HHS R01 AI113075
Abstract
Most patients acutely infected with
Indexed as
Administration, IntravenousAnimalsAtrioventricular BlockChagas DiseaseChlorocebus aethiopsChronic DiseaseDisease Models, AnimalFemaleGlycoproteinsMiceMice, Inbred C57BLNeuraminidaseTrypanosoma cruziVero CellsGlycoproteinsNeuraminidasetrans-sialidase
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.